5mju
From Proteopedia
(Difference between revisions)
m (Protected "5mju" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Structure of the thermostabilized EAAT1 cryst mutant in complex with the competititve inhibitor TFB-TBOA and the allosteric inhibitor UCPH101== | |
| - | + | <StructureSection load='5mju' size='340' side='right' caption='[[5mju]], [[Resolution|resolution]] 3.71Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5mju]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MJU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5MJU FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6Z6:2-AMINO-5,6,7,8-TETRAHYDRO-4-(4-METHOXYPHENYL)-7-(NAPHTHALEN-1-YL)-5-OXO-4H-CHROMENE-3-CARBONITRILE'>6Z6</scene>, <scene name='pdbligand=7O9:(2~{S},3~{S})-2-AZANYL-3-[[3-[[4-(TRIFLUOROMETHYL)PHENYL]CARBONYLAMINO]PHENYL]METHOXY]BUTANEDIOIC+ACID'>7O9</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5mju FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mju OCA], [http://pdbe.org/5mju PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5mju RCSB], [http://www.ebi.ac.uk/pdbsum/5mju PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5mju ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/EAA1_HUMAN EAA1_HUMAN]] Alternating hemiplegia of childhood;Episodic ataxia type 6. The disease is caused by mutations affecting the gene represented in this entry. | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/EAA1_HUMAN EAA1_HUMAN]] Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium. | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Assal, R]] | ||
| + | [[Category: Canul-Tec, J]] | ||
| + | [[Category: Legrand, P]] | ||
| + | [[Category: Reyes, N]] | ||
| + | [[Category: Excitatory aminoacid transporter 1]] | ||
| + | [[Category: Human glutamate transporter]] | ||
| + | [[Category: Tfb-tboa]] | ||
| + | [[Category: Transport protein]] | ||
| + | [[Category: Ucph-101]] | ||
Revision as of 13:00, 19 April 2017
Structure of the thermostabilized EAAT1 cryst mutant in complex with the competititve inhibitor TFB-TBOA and the allosteric inhibitor UCPH101
| |||||||||||
